- $4.05bn
- $4.05bn
- $2.47bn
Annual income statement for Minimed, fiscal year end - April 26th, USD millions except per share, conversion factor applied.
2023 April 28th | 2024 April 26th | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 2,245 | 2,469 |
| Cost of Revenue | ||
| Gross Profit | 1,308 | 1,437 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 2,314 | 2,538 |
| Operating Profit | -69 | -69 |
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -76 | -70 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -92 | -108 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | -97 | -113 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -96 | -112 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.219 | -0.327 |